Nakazawa et al., 2021, demonstrated that tumor-derived EVs containing CD300a are taken up by dendritic cells resulting in their inhibited secretion of interferon-β (IFN-β) leading to enhanced tumor immunity via the decreased activation of regulatory T cells [151]. This evidence concerns the gene CD300A and neoplasm.